Advances in understanding the innate immune‐associated diabetic kidney disease. Issue 2 (28th January 2021)

• Record Type: Journal Article
• Authors: Wan, Shengfeng; Wan, Shengkai; Jiao, Xiaojing; Cao, Huixia; Gu, Yue; Yan, Lei; Zheng, Yan; Niu, Peiyuan; Shao, Fengmin
• Is Part Of: FASEB journal. Volume 35:Issue 2(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-01-28
• Subjects: diabetic kidney disease -- innate immunity -- therapy; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.202002334R
• Languages: English
• ISSNs: 0892-6638

Abstract

Abstract: Millions of human deaths occur annually due to chronic kidney disease, caused by diabetic kidney disease (DKD). Despite having effective drugs controlling the hyperglycemia and high blood pressure, the incidence of DKD is increasing, which indicates the need for the development of novel therapies to control DKD. In this article, we discussed the recent advancements in the basic innate immune mechanisms in renal tissues triggered under the diabetes environment, leading to the pathogenesis and progression of DKD. We also summarized the currently available innate immune molecules‐targeting therapies tested against DKD in clinical and preclinical settings, and highlighted additional drug targets that could potentially be employed for the treatment of DKD. The improved understanding of the disease pathogenesis may open avenues for the development of novel therapies to rein in DKD, which consequently, can reduce morbidity and mortality in humans in the future.